Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
Haddad RI, Seiwert TY, Chow LQM, Gupta S, Weiss J, Gluck I, Eder JP, Burtness B, Tahara M, Keam B, Kang H, Muro K, Albright A, Mogg R, Ayers M, Huang L, Lunceford J, Cristescu R, Cheng J, Mehra R. Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma. Journal For ImmunoTherapy Of Cancer 2022, 10: e003026. PMID: 35217573, PMCID: PMC8883256, DOI: 10.1136/jitc-2021-003026.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenFemaleHead and Neck NeoplasmsHumansImmunotherapyMaleSquamous Cell Carcinoma of Head and NeckTranscriptomeTumor BurdenConceptsNeck squamous cell carcinomaSquamous cell carcinomaPD-L1P16 immunohistochemistryCell carcinomaAnti-programmed death-1 therapyRecurrent/metastatic headInflammatory gene expression profileTumor human papillomavirus (HPV) statusPD-L1 CPSHuman papillomavirus (HPV) statusPD-L1 expressionRandomized clinical trialsTumor mutational burdenPretreatment tumor samplesWhole-exome sequencingM HNSCCMetastatic headClinical responseHPV resultsHPV statusInflammatory biomarkersObjective responseClinical outcomesClinical trials